Oncotarget

Research Papers:

Toll-like receptor 3 pathway restricts Marek’s disease virus infection

Haitao Zou, Ruixue Su, Jing Ruan, Hongxia Shao, Kun Qian, Jianqiang Ye and Aijian Qin _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:70847-70853. https://doi.org/10.18632/oncotarget.20003

Metrics: PDF 1738 views  |   HTML 2047 views  |   ?  


Abstract

Haitao Zou1,2, Ruixue Su1,2, Jing Ruan1,2, Hongxia Shao1,2,3, Kun Qian1,2,3, Jianqiang Ye1,2,3 and Aijian Qin1,2,3

1Ministry of Education Key Lab for Avian Preventive Medicine, Yangzhou University, Yangzhou, Jiangsu, 225009, P.R. China

2Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, Jiangsu, 225009, P.R. China

3Jiangsu Key Lab of Zoonosis, Yangzhou, Jiangsu, 225009, P.R. China

Correspondence to:

Aijian Qin, email: [email protected]

Keywords: Marek’s disease virus, toll-like receptor 3, poly (I:C), interferon-β, inflammatory cytokines

Abbreviations: IRF3: interferon regulatory factor3, IKKα: IκB kinase α, TANK: TRAF family member-associated NFκB activator

Received: April 04, 2017     Accepted: July 12, 2017     Published: August 07, 2017

ABSTRACT

Marek’s disease virus (MDV) is an α-herpesvirus that causes immune suppression and T lymphoma in chickens. Toll-like receptor 3 (TLR3) is critical for the host immune response against MDV infection. Previously, our team demonstrated that pre-treatment of TLR3 agonist poly (I:C) inhibited Marek’s disease virus infection in chicken embryo fibroblasts (CEFs). However, whether TLR3 inhibits the aggravation of MDV infection is unknown. In the current study, we found that TLR3 activation in MDV-infected CEFs effectively inhibited virus spread. Using pharmacological approaches, we revealed that pro-inflammatory cytokines and interferon-β induced by TLR3 could restrict Marek’s disease virus infection. This study contributes to elucidating the function and mechanism of the TLR3 pathway in host immune responses against MDV infection.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20003